Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Functional characterization of plant cellular IRES in response to abiotic stress and their use as biotechnological tools (PLANT CIRES BIOTECH)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Applied life sciences and biotechnology
Countries involved: Spain
Call:  (ERC-2010-StG_20091118, 2010)
Start date: 2010-12-01
End date: 2017-05-31
Duration (months): 78.0
Total project cost (EUR): 1237500.0
EU funding (EUR): 1237500.0
Participants: 1
Project status: CLOSED

To cope with abiotic stresses plants require an extensive molecular regulation of gene expression. In plants, translation is a key step in the control of gene expression under abiotic stress conditions. This translational regulation involves (1) a global inhibition of protein synthesis and (2) an efficient and selective translation of certain mRNAs, generally codifying proteins involved in the abiotic stress response. Although in plants the mechanisms involved in the onset of this dual regulation are currently unknown, some evidences point out that cap independent translation, via recognition of internal ribosome entry sites (IRES) within the mRNAs efficiently translated, could be the clue for the selective protein synthesis observed under such conditions. In this proposal we aim to further characterize the cellular IRESs operating under abiotic stress conditions in plants and to exploit the identified cellular IRESs as biotechnological tools to allow the efficient and selective translation of mRNAs of interest under abiotic stress conditions. In plants, no IRES trans-acting factors (ITAFs) and only two cellular IRESs have been identified so far. Therefore, the systematic identification of new cellular IRESs, the identification for the first time of ITAFs and the study of how they can control IRES activity-specificity under abiotic stress conditions are important steps forward in the knowledge of how plants adapt to environmental stresses. In addition, the pioneering use of the identified cellular IRESs as a tool to tightly and specifically control the expression of proteins of interest under abiotic stress conditions will open up a new perspective for the study of abiotic stress in plants and for the generation of plants with increased tolerance to such conditions.

Keywords: plant molecular biology,translation,internal ribosome entry sites (ires),ires trans-acting factors (itafs),abiotic stress.
KRas mutation interactions with host immunity in malignant pleural effusion. (KRASHIMPE)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Physiology, Pathophysiology and Endocrinology
Countries involved: Greece
Call:  (ERC-2010-StG_20091118, 2010)
Start date: 2011-04-01
End date: 2016-03-31
Duration (months): 60.0
Total project cost (EUR): 1995000.0
EU funding (EUR): 1995000.0
Participants: 1
Project status: CLOSED

Malignant pleural effusion (MPE) is a significant problem most commonly caused by adenocarcinomas. Although tumors involving the pleura vary in their ability to produce MPE, pathways critical for MPE formation are poorly defined. We have found that mouse tumors harboring mutant (”)KRas produce MPE in mice while tumors without ”KRas do not. LLC and MC38 lung and colon adenocarcinomas, potent inducers of MPE in syngeneic mice, harbor ”KRas that drives constitutive Ras and alternative nuclear factor (NF)-ºB signaling, inflammatory gene expression, and recruitment of specific myeloid cells to the pleural space. In contrast, mouse B16 melanoma and AE17 mesothelioma have wtKRas, lack constitutive Ras/alternative NF-º’ signaling, and are incapable of forming MPE. RNAi-mediated silencing of KRas in MC38 tumors abrogated MPE formation and Ras/alternative NF-º’ activation, while these phenomena were reconstituted in B16 tumors after KRas overexpression. We hypothesize that Ras-activating mutations drive the inflammatory phenotype of adenocarcinomas critical for MPE formation, which is characterized by Ras/alternative NF-ºB activation, inflammatory signalling to host vasculature/immune system, and recruitment of specific myeloid cells, and results in endothelial proliferation/leakiness. To test this hypothesis, we propose to: 1) define the relationship between Ras-activating mutations (RAM) and MPE formation; 2) identify tumor cell Ras-dependent signalling pathways and gene expression signature critical for MPE formation; 3) investigate the host response to tumor cells with RAM that results in MPE; and 4) target Ras and dependent signalling pathways as potential therapy for MPE. Studies will be performed using delivery of mouse/human tumors with/without RAM into the pleura of syngeneic/immunocompromized mice and are likely to yield new insights into the mechanisms of pleural tumor progression and to identify novel approaches to treatment of cancer patients with MPE.

Keywords: lung cancer,adenocarcinoma,pleural diseases,malignant pleural effusion,kras,nf-??,paracrine,inflammation
Small RNA-guided complex machinery for epigenetic silencing (PISILENCE)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Molecular and Structural Biology and Biochemistry
Countries involved: Germany
Call:  (ERC-2010-StG_20091118, 2010)
Start date: 2011-01-01
End date: 2016-05-31
Duration (months): 65.0
Total project cost (EUR): 902849.0
EU funding (EUR): 902849.0
Participants: 1
Project status: CLOSED

Transposons are parasitic DNA elements that when activated can insert into new genomic locations, leading to genome instability. Animal germlines express a special class of small RNAs called piwi-interacting RNAs (piRNAs) which are implicated in transposon silencing. In mammals, they are believed to promote DNA methylation of transposon-rich genomic regions. Mechanisms of piRNA biogenesis and function are only beginning to be understood. Sequence analysis of piRNAs from a variety of organisms has given rise to working models for piRNA biogenesis and how piRNAs might act as guides for nuclear silencing complexes. However, key components of the pathway, especially those for biogenesis and function, remain to be discovered. Our aim is to identify and characterize new components using a combination of biochemistry, mouse genetics and small RNA bioinformatics. The regulatory potential of posttranslational modification of piwi proteins and their recognition by tudor proteins will be examined. Mouse mutants will be used to study the in vivo role of catalytic activity of piwi proteins in piRNA biogenesis and identify putative targets by transcriptomics approaches. Integrated biochemical and deep-sequencing methods will be applied to understand how small RNAs might guide nulcear silencing machinery to target locations. Finally, in a field that is dependent on model organisms, we propose to develop a cell culture system to study the piRNA pathway and carry out a high-throughput functional RNAi screen for component discovery. This proposal aims to use interdisciplinary approaches in uncovering the biochemical framework in which germline small RNAs function to protect eukaryotic genomes.

Keywords: pirnas,piwi,germ cells,dna methylation,tudor,helicases,rnai
Moonlight-dependent Hormones Orchestrating Lunar Reproductive Periodicity and Regeneration (HOR.MOON)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: ERC Starting Grant Interdisciplinary Panel
Countries involved: Austria
Call:  (ERC-2010-StG_20091118, 2010)
Start date: 2010-12-01
End date: 2016-07-31
Duration (months): 68.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: CLOSED

The moon governs reproductive cycles in a broad range of marine animals, including cnidarians, polychaetes, crustaceans, echinoderms and fishes. Even outside the animals, lunar reproductive cycles have been described, such as in brown algae or foraminifers. Despite their fundamental nature, and decades of classical observations, close to nothing is known about the molecular processes that underly these lunar reproductive cycles. We will take advantage of the recent advance in molecular resources and tools in the bristle worm Platynereis dumerilii, which has long served as a key model for classical experimental studies on lunar periodicity. The combination of modern techniques with well-founded classical observations will allow us to decipher, for the first time, the hormonal cues that are regulated by the lunar cycle and are responsible for the orchestration of gonadal maturation and trunk regeneration. The project builds on established methodology, as well as on the first results of a successful pioneer screen and has three major aims: (1) the functional investigation of two hormones we recently identified to be under lunar cycle control. (2) the extension of our successful pioneer screen to understand to which extent other neurohormonal components change over the lunar phase. (3) the identification of the elusive inhibitory brain hormone that directly acts on the gonads to inhibit premature maturation. Together, these experiments will lead us to first significant insights into the molecular nature of the hormonal network that underlies moonlight-dependent periodicity and regeneration.

Keywords: marine biology,lunar periodicity,chronobiology,hormone,annelids
Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: United Kingdom,Netherlands,Germany,United Kingdom,United Kingdom,Germany,Ireland,Belgium,Italy,France,Hungary,Italy,United Kingdom,Netherlands,United Kingdom
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2010-11-01
End date: 2016-04-30
Duration (months): 66.0
Total project cost (EUR): 3929356.44
EU funding (EUR): 2999559.6
Participants: 17
Project status: CLOSED

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children, affecting approximately 5% children in Europe. Methylphenidate (MPH) is the most-commonly prescribed medication for ADHD children; it is also increasingly used in ADHD adults. In 2007, the European Commission requested a referral to the Committee for Medicinal Products for Human Use (CHMP) under Article 31 of Directive 2001/83/EC, as amended, for MPH because of safety concerns. The CHMP concluded that study of the long-term effects of MPH on growth, sexual development, neurological system, psychiatric states and cardiovascular system is needed. In response to the CHMP’s concerns, the ADDUCE (Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects) research team has been formed by a consortium of experts in the fields of ADHD, drug safety, neuropsychopharmacology and cardiovascular research. The ADDUCE project aims to investigate the long-term adverse effects of MPH on growth, neurological system, psychiatric states and cardiovascular system in children and adults. The ADDUCE team will use multiple pharmacoepidemiological research methods to achieve its aim: (1) Retrospective analysis of existing databases. (2) 2-year prospective cohort study recruiting 800 MPH-treated children and adolescents and 800 controls. (3) Cross-sectional study (600 MPH-treated patients and 600 controls) in late adolescents and young adults. Furthermore the ADDUCE team will develop research tools for the evaluation of adverse effects of MPH on cognition and motivation. The ADDUCE consortium comprises 12 academic partners, 1 SME and 1 EU professional network. The ADDUCE team will directly interact with the European Medicines Agency to assist them in making regulatory decisions on the safety of MPH in children and adults. The ADDUCE team will adopt an open-access policy to ensure the information and results have the maximum public health impact.

Keywords: adhd,methylphenidate,long-term safety,children,adolescents,young adults.
Immunogenomics: Mouse to Human Translational Research (IMMUNO)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Immunity and infection
Countries involved: Belgium
Call:  (ERC-2010-StG_20091118, 2010)
Start date: 2011-04-01
End date: 2016-03-31
Duration (months): 60.0
Total project cost (EUR): 1496687.87
EU funding (EUR): 1496687.87
Participants: 1
Project status: CLOSED

Control over the activation of the immune system is central to the key issues of human health. Autoimmunity, atopy, persistent infections and tumours all share a common root cause in a sub-optimal balance between immune activity and tolerance. At the heart of this balance are T cells, with the capacity for both activation and suppression. Research in mouse models has allowed enormous progress to be made on understanding fundamental mechanics, and yet the next step translating this understanding into therapeutics has proven far more difficult than originally anticipated. The basis of this problem may be a reliance on the mouse model without parallel human research. In this project we propose to create a dynamic interplay between the technological advantages of working in mouse models and the physiological relevance of studying the human immune system in three key research areas. The first research track is a gene discovery program, using an immunology-orientated approach to allow the discovery of important human disease genes that remain invisible to clinically-orientated approaches. The second research track is a functional genomics program, seeking to address the mechanistic questions that arise from traditional disease-gene association studies. This information is of critical importance in translating genetic data into therapeutic interventions and provides the basis for personalised medicine. The third research track is a direct hypothesis-driven project testing the role that genetic variation in the target organ alters susceptibility to autoimmune disease. Each of these research tracks utilises cutting edge technology in genetics and immunology, combining knowledge from mouse models with innovative study design in human populations.

Keywords: diabetes,immunodeficiency,colitis,t cell,genetics
Microvesicle-inspired drug delivery systems (MINDS)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Diagnostic tools, therapies and public health
Countries involved: Netherlands
Call:  (ERC-2010-StG_20091118, 2010)
Start date: 2010-12-01
End date: 2015-11-30
Duration (months): 60.0
Total project cost (EUR): 1338000.0
EU funding (EUR): 1338000.0
Participants: 2
Project status: CLOSED

Current state-of-the-art drug carrier systems deliver new ‘biological drugs’ (like proteins and nucleic acids) poorly to the target site. This is something I daily experience in my research on delivery of small interfering RNA. The in vivo challenges are threefold: • Biological drugs are fragile molecules (subject to degradation and denaturation) • They need to gain access to the target site • They need delivery to a specific cell type and even to a specific subcellular location to be active. Recent research points out an endogenous communication system transporting proteins and nucleic acids between cells, outperforming current synthetic drug delivery systems. These carriers, known as microvesicles, appear Nature’s choice for delivery of biologicals and have created excitement in the research community. Microvesicles encompass a variety of submicron vesicular structures that include exosomes, shedding vesicles, and microparticles. The lipids, proteins, mRNA and microRNA delivered by these microvesicles change the phenotype of the receiving cells. Microvesicles appear to play an important role in many disease processes, most notably inflammation and cancer, where their efficient functional delivery of biological cargo contributes to the disease progress. Up to now, most research addresses the role of microvesicles in cell biology. At the same time, surprisingly little is known about their in vivo kinetics, targeting behavior and tissue distribution from a drug carrier standpoint. The aim of my proposal is to design and develop microvesicle-inspired drug delivery systems to improve targeting and delivery of biological drugs. The work plan is divided into two approaches: 1-A synthetic approach based on liposomes or isolated microvesicle constituents 2-A biological approach based on biotechnologically-engineered and cell-produced microvesicles. The results of this research are expected to improve insights into in vivo behavior of microvesicles and the critical molecules that trigger their delivery and targeting success. It should also be clear which of the two approaches is best suited for the production of pharmaceutically acceptable microvesicle-mimics. Finally, the research should result in a prototype microvesicle-inspired carrier. These results can form the basis for an attractive new generation of microvesicle mimicking drug delivery systems.

Keywords: drug delivery,drug targeting,microvesicles,mirna,sirna,liposomes,artificial microvesicles,exosomes,microparticles,(phospho)lipids,phosphatidylserine,mrna,biologicals,biopharmaceuticals
Intra-patient evolution of HIV (HIVEVO)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Evolutionary, population and environmental biology
Countries involved: Germany,Sweden
Call:  (ERC-2010-StG_20091118, 2010)
Start date: 2011-03-01
End date: 2016-02-29
Duration (months): 60.0
Total project cost (EUR): 1155859.0
EU funding (EUR): 1155859.0
Participants: 2
Project status: CLOSED

HIV is one of the most rapidly evolving organisms known. Understanding its evolutionary dynamics is essential for successful drug treatment or vaccine design. At the same time, this rapid evolution makes HIV an ideal model system to study fundamental problems in evolutionary dynamics: In HIV, one can directly observe evolution over genetic distances that correspond to millions of years of evolution in other organisms. This proposal combines time series of ultra-deep sequence data of HIV from individual patients, functional information on drug resistance, and methods from statistical physics to study evolution. The sequence data will observe the dynamics of the genotype distribution in the population, while the exceptionally well characterized biology of HIV will allow the assignment of functional significance to the observed genotypic changes. These two levels of description will be integrated by theoretical models that describe how selection on phenotypes feeds back on the genotype distribution. Specifically, we will determine the fundamental parameters of HIV evolution such as selection strength, recombination rates, and the patterns of genetic interactions from the time resolved data obtained by deep sequencing. We will use the data base of viral sequences that evolved in response to drug treatment to infer the fitness landscapes of drug resistance. These two projects will be integrated in a quantitative model of drug resistance evolution. In a third project, we will quantify how genetic interactions affect the formation of circulant recombinant forms of HIV. Using HIV as a model system, we will develop and test theories of multi-locus evolution, characterize fitness landscapes and genetic interactions, and quantify the impact of recombination on HIV evolution.

Keywords: hiv evolution statistical physics and evolution
Promoting participation of high-tech research-intensive SMEs in Health (FIT FOR HEALTH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Austria,Hungary,Switzerland,Germany,Greece,Bulgaria,Cyprus,Czechia,France,Germany,Israel,Italy,Poland,Spain,Spain,Sweden,Türkiye,Netherlands,Estonia,Belgium,Belgium,Croatia,Estonia,Latvia,Romania,United Kingdom
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2010-10-01
End date: 2013-09-30
Duration (months): 36.0
Total project cost (EUR): 2277919.6
EU funding (EUR): 1937120.0
Participants: 29
Project status: CLOSED

Fit for Health aims to sustainably enhance the participation of European small or medium-sized enterprises (SMEs) in Calls for the FP7 Health Theme. Focusing on research-intensive, high technology SMEs, the project offers targeted support measures, covering the entire innovation pipeline of the Health sector. Key assets of Fit for Health are highly qualified consultancy, hands-on trainings, effective SME-academia matchmaking and guidance to strategic use of FP7 by SMEs and clusters. Particular attention will be given to SMEs in enlarged Europe, Acceding and Candidate countries. SMEs and researchers will be supported during all phases of FP7-projects, including consortium building, proposal writing, grant negotiation, project management and efficient valorisation of project results. Cooperation between SMEs and academia will be strongly encouraged by dedicated services and tools. A well-established, highly visible database and a sophisticated matchmaking-tool, already proven in preceding initiatives, will support the formation of competitive project consortia. Partnering Days and Virtual Brokerage Events will provide excellent interaction platforms for SMEs and academia. Target group-specific on-site and virtual trainings for FP7 Newcomers, Applicants and participants of funded FP7 projects will be a hallmark of the project. “Valorisation Trainings” and specific Partnering Events will support SMEs and researchers in successfully exploiting project results. Strategy meetings and trainings will support SMEs and clusters for a strategic, sustainable approach towards FP7. The consortium of 27 partners from 22 countries joins highly experienced FP7 NCPs for “Health” and “SMEs” with renowned innovation experts and trainers, ensuring excellent coverage of the entire innovation pipeline. Strategic Third Parties contribute the perspective of Venture Capital and Bank Financing. The efficiently managed network is also optimally connected to other key support networks for SMEs.

Keywords: health,life sciences,training,matchmaking,valorisation,database,strategy,academia,cluster